PriceTargets.com logo

Odonate Therapeutics - ODT Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: NaN
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.00 As of 02/3/2022 01:00 AM ET
+0 (0.00%)
Get New Odonate Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ODT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ODT

Analyst Price Target is $0.00
This price target is based on 0 analysts offering 12 month price targets for Odonate Therapeutics in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a NaN upside from the last price of $0.00.

This chart shows the closing price for ODT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 polled investment analysts is to n/a stock in Odonate Therapeutics. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/2/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/31/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/1/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/30/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/28/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/26/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/26/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/25/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/22/2021Lifesci CapitalDowngradeOutperform ➝ Market PerformHigh
3/22/2021The Goldman Sachs GroupLower TargetSell$11.00 ➝ $4.00High
3/22/2021Jefferies Financial GroupDowngradeBuy ➝ Hold$45.00 ➝ $4.00N/A
3/22/2021CowenDowngradeOutperform ➝ Market PerformN/A
10/28/2020Lifesci CapitalReiterated RatingOutperformLow
9/9/2020Ci CapitalReiterated RatingBuy$50.00Medium
12/6/2019The Goldman Sachs GroupInitiated CoverageSell$26.00High
6/3/2019CowenReiterated RatingBuyHigh
(Data available from 4/26/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/29/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/29/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/28/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/28/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/27/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/26/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/27/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/26/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Odonate Therapeutics logo
Odonate Therapeutics is a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer. Our initial focus is on the development of tesetaxel, a novel chemotherapy agent that belongs to a class of drugs known as taxanes, which are widely used in the treatment of cancer. Tesetaxel has several potential therapeutic advantages over currently available taxanes, including: oral administration with a low pill burden and a patient-friendly dosing regimen; a formulation that does not contain solubilizing agents that are known to cause hypersensitivity (allergic) reactions; and improved activity against chemotherapy-resistant tumors. Tesetaxel has been generally well tolerated in clinical studies and has demonstrated robust single-agent antitumor activity in two Phase 2 studies in patients with locally advanced or metastatic breast cancer (''MBC'').
Read More

Today's Range

Now: N/A

50 Day Range

MA: $1.27
Low: $1.03
High: $1.55

52 Week Range

Now: N/A

Volume

87,682 shs

Average Volume

N/A

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Odonate Therapeutics?

The following Wall Street sell-side analysts have issued research reports on Odonate Therapeutics in the last year:
View the latest analyst ratings for ODT.

What is the current price target for Odonate Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Odonate Therapeutics in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Odonate Therapeutics in the next year.
View the latest price targets for ODT.

What is the current consensus analyst rating for Odonate Therapeutics?

Odonate Therapeutics currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for ODT.

What other companies compete with Odonate Therapeutics?

Other companies that are similar to Odonate Therapeutics include Context Therapeutics, Grifols, LAVA Therapeutics, Mainz Biomed and NLS Pharmaceutics. Learn More about companies similar to Odonate Therapeutics.

How do I contact Odonate Therapeutics' investor relations team?

Odonate Therapeutics' physical mailing address is 4747 EXECUTIVE DRIVE SUITE 510, SAN DIEGO CA, 92121. The company's listed phone number is (858) 731-8180 and its investor relations email address is [email protected]. The official website for Odonate Therapeutics is www.odonate.com. Learn More about contacing Odonate Therapeutics investor relations.